Head to Head Comparison: SBC Medical Group (NASDAQ:SBC) & Oncology Institute (NASDAQ:TOI)

Oncology Institute (NASDAQ:TOI) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Risk and Volatility

Oncology Institute has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Earnings & Valuation

This table compares Oncology Institute and SBC Medical Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$378.93 million	0.06	-$83.07 million	($0.78)	-0.39
SBC Medical Group	$223.34 million	2.36	$340,000.00	N/A	N/A

SBC Medical Group has lower revenue, but higher earnings than Oncology Institute.

Profitability

This table compares Oncology Institute and SBC Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-17.63%	-186.83%	-34.58%
SBC Medical Group	N/A	-11.59%	-7.05%

Analyst Ratings

This is a summary of current ratings and recommmendations for Oncology Institute and SBC Medical Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	0	0	1	0	3.00
SBC Medical Group	0	0	0	0	0.00

Oncology Institute presently has a consensus target price of $2.50, suggesting a potential upside of 728.64%. Given Oncology Institute’s stronger consensus rating and higher probable upside, research analysts plainly believe Oncology Institute is more favorable than SBC Medical Group.

Institutional and Insider Ownership

36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 9.5% of Oncology Institute shares are held by insiders. Comparatively, 63.9% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SBC Medical Group beats Oncology Institute on 8 of the 12 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.